Resources
Related Tags:
Dynex Capital Inc. (10 results)
- sort by:
- Relevance
- Date
- Popularity
- Juniper Networks Advances Secure and Assured Data Center Application Delivery; New Juniper Networks DX Platform Delivers New Acceleration and Management Features
- SUNNYVALE, Calif. -- Juniper Networks, Inc. (Nasdaq:JNPR) today announced a new version of operating system software for the DX, Juniper Networks' data center application acceleration platform, which enables customers to enhance the performance of applications centralized in data centers. The new DX operating system software, DXOSTM version 5.1, enables all...
- Research articles 2006-02-13
- DX AND ORACLE COOPERATE ON ELECTRIC POWER
- AsiaInfo Services 03-03-2004 DX and Oracle Cooperate on Electric Power CHINA, Mar 03, 2004 SinoCast via COMTEX -- Oracle Taiwan and Beijing-based Datang Xingzhu DX announced on February 27 that they had partnered to provide with integrated AsiaInfo Services...
- Research articles 2004-03-03
- CANDOVER INVESTMENTS PLC - cancellation of listing - DX Services PLC.
- DX Services PLC - Cancellation of Listing Immediate release NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO CANADA, AUSTRALIA OR JAPAN 21 September 2006 Recommended cash offer for DX Services plc by Mail Acquisitions Limited ...
- Research articles 2006-09-21
- LTX Announces Fusion DX - the First Desktop SOC Tester; New Fusion Configuration Extends LTX's Scalable, Single-Platform Architecture
- WESTWOOD, Mass. -- LTX, a leading provider of semiconductor test equipment, today announced the release of Fusion DX, the first desktop tester for system-on-a-chip SOC devices. Built on LTX's scalable, single-platform architecture, Fusion DX provides a powerful ATE solution that can be used for both design validation and volume production...
- Research articles 2004-06-21
- Dyax Corp. Expands Patent Protection for DX-88 in On-Pump Cardiothoracic Surgery
- CAMBRIDGE, Mass. -- Dyax Corp. (NASDAQ: DYAX) announced today the issuance of a U.S. patent for its lead product candidate DX-88, a non-naturally occurring kallikrein inhibitor, and its uses. U.S. Patent No. 7,235,530 (issued June 26, 2007), relates to the company's DX-88 program in on-pump cardiothoracic surgery CTS, and provides...
- Research articles 2007-07-19
- Piracy May Be the Kindle DX's Savior
- Jason Kincaid submits: Earlier this week, we got our first glimpse of the Kindle DX, Amazon’s AMZN upcoming E-book reader that has taken the original Kindle’s nearly prohibitive $359 price tag and bumped it up to an even more exorbitant $489 for good measure. Granted, the DX...
- External links 2009-05-10
- Kindle DX: Higher Expectations from the Bigger Screen
- Larry Dignan ZDNet submits: Amazon’s AMZN Kindle DX is an interesting study in user expectations. The limitations of the Kindle 2 aren’t nearly as acceptable on a bigger screen. The Kindle DX has a 9.7-inch screen, which is larger than the Kindle 2’s 6-inch version. The other...
- External links 2009-06-15
- Desert Aire releases new brochure—"Technical Bulletin 20—DX-DOAS control strategy"
- DX-DOAS Control Strategy, Technical Bulletin 20, describes the company's control options for DX dedicated outdoor air systems (DX-DOAS) and the necessary sequences to maintain comfortable indoor conditions while introducing outdoor air that meets the ASHRAE 62. Control strategies are explained to help specifiers select the most economical system for their...
- Research articles 2007-10-01
- Desert Aire releases new brochure—"Technical Bulletin 20—DX-DOAS Control Strategy"
- DX-DOAS Control Strategy, Technical Bulletin 20, describes the company's control options for DX dedicated outdoor air systems (DX-DOAS) and the necessary sequences to maintain comfortable indoor conditions while introducing outdoor air that meets the ASHRAE 62. Control strategies are explained to help specifiers select the most economical system for their...
- Research articles 2008-05-01
- Desert Aire releases revised brochureÂ?"Technical Bulletin 20Â?DX-DOAS Control Strategy"
- DX-DOAS Control Strategy, Technical Bulletin 20, describes the company's control options for DX dedicated outdoor air systems (DX-DOAS) and the necessary sequences to maintain comfortable indoor conditions while introducing outdoor air that meets the ASHRAE 62. Updated control strategies are explained to help specifiers select the most economical...
- Research articles 2009-01-01
- Amazon Combines Kindle 2, Global; AT&T Replaces Sprint On New Models; International DX In 2010
- That $20 price drop for the international Kindle goes a little deeper than the obvious competitive move; it was the company’s way of signaling that Kindle 2 and global Kindle are the same device. The conceit that there were two was a distinction without a difference save in one...
- External links 2009-10-23
- Portable Medical Records in the Palm of Your Hand from Dx-PRN
- CLEVELAND -- An innovative portable medical records system that fits in the palm, pocket or purse is now available through Dx-PRN. Designed primarily for people with chronic or acute illnesses, Dx-PRN's device holds a complete medical file that is especially useful in an emergency or while traveling. Parents who have...
- Research articles 2005-07-12
- Dyax and Genzyme Initiate Pivotal Phase III Trial of Subcutaneously Administered DX-88 for the Treatment of Hereditary Angioedema
- CAMBRIDGE, Mass. -- Dyax Corp. (Nasdaq:DYAX) and Genzyme Corporation (Nasdaq:GENZ) announced today that patient treatment has begun in their pivotal Phase III clinical trial of Dyax's recombinant plasma kallikrein inhibitor known as DX-88. In this trial, referred to as EDEMA3, DX-88 is being studied for the treatment of patients with...
- Research articles 2005-12-08
- Dyax Provides Update on DX-88 Development for Hereditary Angioedema; Advances Subcutaneous Route of Administration
- CAMBRIDGE, Mass. -- Dyax Corp. (Nasdaq: DYAX) today reported on the status of its clinical development program for DX-88 in hereditary angioedema HAE, which is in a joint venture with Genzyme Corporation. Following on positive preclinical study results, Dyax is advancing DX-88 into a clinical trial in normal volunteers to...
- Research articles 2005-03-28
- Dyax and Genzyme Reaffirm Positive Market Outlook for DX-88 for the Treatment of Hereditary Angioedema; Conference Call Scheduled for 10 am Today
- CAMBRIDGE, Mass. -- Dyax Corp. (Nasdaq:DYAX) announced that it will host a conference call at 10 am EST today, to expand upon statements made with regard to the market demand for DX-88 for the treatment of hereditary angioedema HAE during Genzyme Corporation's July 14 second quarter earnings call. DX-88 is...
- Research articles 2004-07-19
- CardioDynamics Receives FDA 510k Clearance for BioZ Dx; Partnership with Philips Medical Leads to First ICG Device with Patented AERIS Processing
- SAN DIEGO -- CardioDynamics (Nasdaq:CDIC), the innovator and leader of Impedance Cardiography ICG technology, today announced its new product platform, the BioZ DxTM, has received market clearance from the U.S. Food and Drug Administration FDA. Market introduction of the BioZ Dx will take place immediately.
- Research articles 2004-12-15
- Dyax Corp. Receives Composition of Matter Patent for Lead Product Candidate DX-88
- CAMBRIDGE, Mass. -- Dyax Corp. (NASDAQ: DYAX) announced today the issuance of U.S. Patent No. 7,276,480, covering the composition of matter for its lead product candidate DX-88, a recombinant small protein discovered from the Company's proprietary phage display technology, to which Dyax owns the worldwide rights. The recently issued patent...
- Research articles 2007-10-04
- Dyax Corp. Issued Two Patents for Use of DX-88 in CTS
- CAMBRIDGE, Mass. -- Dyax Corp. (Nasdaq:DYAX) announced today that the United States Patent and Trademark office has issued two U.S. Patents relating to its program for on-pump cardiothoracic surgery CTS. U.S. Patent No. 7,153,829 (issued December 26, 2006) covers methods for preventing or reducing perioperative blood loss due to surgery...
- Research articles 2007-01-09
- Dyax Initiates Confirmatory Phase 3 Trial for DX-88 for the Treatment of Hereditary Angioedema
- CAMBRIDGE, Mass. -- Dyax Corp. (Nasdaq:DYAX) announced today that patient treatment has begun in the Phase 3 confirmatory trial, known as EDEMA4, for its lead product candidate, DX-88 ecallantide. DX-88, an internally discovered, recombinant, plasma kallikrein inhibitor, is in clinical trials for the treatment of acute attacks of hereditary angioedema...
- Research articles 2007-04-17
- SMART Modular Technologies Targets Kiosk, ATM and Digital Signage With XceedPC(TM)/Dx Family
- SMART Modular Technologies WWH, Inc. SMART (NASDAQ: SMOD), a leading independent manufacturer of memory modules, solid state drives, embedded computing subsystems, and TFT-LCD display products, announced today its XceedPC/Dx line of high-performance embedded PCs using Intel® Socket 775 CPUs. The RoHS-compliant XceedPC/Dx line combines high performance, cost-effective CPUs with...
- Research articles 2008-04-14
- << Previous
- page 1 of 18
- Next >>
Presented by American Express